Peter Riedell, MD

Experts share their closing thoughts and key take-home messages from this discussion.

Experts discuss the challenges and barriers in early referral for chimeric antigen receptor T-cell therapy (CAR T) and how post–CAR T follow-up care is managed between academic and community settings.

Experts discuss recent data updates from the TRANSCEND CLL-004 study on the combination of lisocabtagene maraleucel (liso-cel) and ibrutinib, the potential curative role of chimeric antigen receptor T-cell therapy (CAR T) in relapsed/refractory chronic lymphocytic leukemia (R/R CLL), and the future outlook for CAR T in treating R/R CLL.

Experts discuss novel combination therapies in first-line chronic lymphocytic leukemia (CLL) and their potential impact on treatment sequencing and patient outcomes.

Experts discuss when to consider chimeric antigen receptor T-cell therapy (CAR T) for relapsed/refractory chronic lymphocytic leukemia (R/R CLL) patients and how to sequence CAR T and pirtobrutinib in clinical practice for those who have previously received both covalent Bruton tyrosine kinase (cBTK) inhibitor– and BCL2 inhibitor–containing regimens.

Experts discuss key points to share with patients when counseling or first introducing chimeric antigen receptor T-cell therapy (CAR T), focusing on expectations, potential adverse effects, and the treatment process.

Experts discuss key points to share with patients when counseling or first introducing chimeric antigen receptor T-cell therapy (CAR T), focusing on expectations, potential adverse effects, and the treatment process

Experts discuss sequencing treatments in the third-line setting or beyond for patients who have not received chimeric antigen receptor T-cell therapy (CAR T) previously, comparing bispecific antibodies, CAR T, and other agents like polatuzumab and tafasitamab, while also considering patient factors and disease characteristics when selecting among available CAR-T options (axicabtagene ciloleucel [axi-cel], lisocabtagene maraleucel [liso-cel], and tisagenlecleucel [tisa-cel]).

Experts discuss real-world outcomes of lisocabtagene maraleucel (liso-cel) as second-line therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), including data highlights from the CIMBTR registry and insights from a Matching-Adjusted Indirect Comparison (MAIC) of liso-cel vs axicabtagene ciloleucel (axi-cel) in the second-line setting, examining how these findings influence chimeric antigen receptor T-cell therapy (CAR T) selection and decision-making based on patient factors and disease characteristics.

Experts discuss the use of chimeric antigen receptor T-cell (CAR T) therapies, specifically axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), in the second-line setting for patients with diffuse large B-cell lymphoma (DLBCL), focusing on patient selection and treatment frequency.

Peter Riedell, MD, highlights the rationale for investigating CAR T-cell therapy rapcabtagene autoleucel in relapsed/refractory DLBCL.

Peter Riedell, MD, discusses efficacy and safety of rapcabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.

Peter Riedell, MD, discusses the clinical utility of EZH2 mutation testing when navigating treatment options for patients with relapsed/refractory follicular lymphoma.

Peter Riedell, MD, discusses the use of axicabtagene ciloleucel in high-risk large B-cell lymphoma, as evaluated on the phase 2 ZUMA-12 trial.

Peter Riedell, MD, discusses unique data points of a landmark analysis conducted in mantle cell lymphoma.

Peter Riedell, MD, discusses the patient population and design of a dynamic landmark analysis conducted in patients with mantle cell lymphoma.

Peter Riedell, MD, discusses the effects of time to relapse on outcomes in mantle cell lymphoma.

Peter Riedell, MD, discusses the rationale to evaluate survival outcomes after transplant in mantle cell lymphoma.